News | January 13, 2022
Normalised quarter with impending margin pressure: ICICI Direct
ICICI Direct gives a preview on the earnings narrative for Q3FY22
ICICI Direct gives a preview on the earnings narrative for Q3FY22
He has over 22 years of experience in pharmaceutical sales & business development
ICICI Direct gives an update on the 12 companies that it has covered in the healthcare universe. A report
An amount of Rs. 70.9 crore has been earmarked for funding capital expenditure for the proposed expansion
Number of approved manufacturing sites of Remdesivir in the country has increased from 22 sites to 60
The progress has been encouraging with approvals and launches in the US, EU, Japan, Australia and Emerging Markets. Post Mylan Upjohn (Pfizer) merger, the scope has been extended to China as well.
The next phase of growth in pharma depends on the industry-oriented workforce, risk investment, academic revamp, and creation of R&D hubs, say experts .
The resilient attitude of Indian pharmaceutical companies coupled with quick innovative solutions has ensured consistency in supply chains amid unprecedented challenges
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)